LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 98

Search options

  1. Article ; Online: What is the role of remdesivir in patients with COVID-19?

    Beigel, John H

    Current opinion in critical care

    2021  Volume 27, Issue 5, Page(s) 487–492

    Abstract: Purpose of review: COVID-19 represents an unprecedented public health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The antiviral remdesivir is one component of treating COVID-19. Unfortunately, the trials evaluating ...

    Abstract Purpose of review: COVID-19 represents an unprecedented public health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The antiviral remdesivir is one component of treating COVID-19. Unfortunately, the trials evaluating remdesivir have reported mixed results, leading to uncertainty on when to use remdesivir. This review discusses the trials evaluating the efficacy of remdesivir for COVID-19 and other supporting data to help inform the role of remdesivir in patients with COVID-19.
    Recent findings: Since the start of the pandemic, there have been four randomized trials of remdesivir in treating patients hospitalized with COVID-19. More recently, extensive observational studies have provided supportive data.
    Summary: The majority of trials evaluating remdesivir suggest that remdesivir is effective in the treatment of patients hospitalized with COVID-19. Although there may be a benefit in some subgroups more than others, there is insufficient data to make definitive statements about benefits or lack of benefits in particular groups. Remdesivir has demonstrated clinical benefits such as decreased time in the hospital, lower progression to mechanical ventilation, and decreased utilization of other hospital resources; it is unclear if it reduces mortality, but one randomized controlled trial suggested possible survival benefits. Based on the data available, remdesivir has been approved (or authorized for early use) in 48 countries.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Antiviral Agents/therapeutic use ; Humans ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Language English
    Publishing date 2021-07-30
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1235629-3
    ISSN 1531-7072 ; 1070-5295
    ISSN (online) 1531-7072
    ISSN 1070-5295
    DOI 10.1097/MCC.0000000000000866
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4999: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Erythema and Induration after Mpox (JYNNEOS) Vaccination Revisited.

    Frey, Sharon E / Goll, Johannes B / Beigel, John H

    The New England journal of medicine

    2023  Volume 388, Issue 15, Page(s) 1432–1435

    MeSH term(s) Humans ; Erythema/chemically induced ; Erythema/etiology ; Mpox (monkeypox)/prevention & control ; Vaccination/adverse effects ; Vaccines, Attenuated/adverse effects ; Vaccines, Attenuated/therapeutic use ; Smallpox Vaccine/adverse effects ; Smallpox Vaccine/therapeutic use
    Chemical Substances smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (TU8J357395) ; Vaccines, Attenuated ; Smallpox Vaccine
    Language English
    Publishing date 2023-03-22
    Publishing country United States
    Document type Letter
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2215846
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Polyclonal and monoclonal antibodies for the treatment of influenza.

    Beigel, John H

    Current opinion in infectious diseases

    2018  Volume 31, Issue 6, Page(s) 527–534

    Abstract: Purpose of review: This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials.: Recent findings: At least three ... ...

    Abstract Purpose of review: This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials.
    Recent findings: At least three polyclonal and eight monoclonal antibody products have been tested in clinical trials for the treatment of influenza. Considered across the two classes of therapeutics, these products appear to be safe and well tolerated. However, the efficacy results have been mixed and inconclusive. To date, no products have consistently shown superiority to currently available antivirals.
    Summary: No products within these two classes have been licensed, and several products appear to have stopped further clinical development. There are several ongoing studies that are anticipated to be completed or reported in the next 1-2 years which will be critical for understanding the value of polyclonal and monoclonal antibodies in the treatment of influenza.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Viral/therapeutic use ; Antiviral Agents/therapeutic use ; Humans ; Immunoglobulins, Intravenous ; Influenza, Human/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Viral ; Antiviral Agents ; Immunoglobulins, Intravenous
    Keywords covid19
    Language English
    Publishing date 2018-10-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 645085-4
    ISSN 1473-6527 ; 1535-3877 ; 0951-7375 ; 1355-834X
    ISSN (online) 1473-6527 ; 1535-3877
    ISSN 0951-7375 ; 1355-834X
    DOI 10.1097/QCO.0000000000000499
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2462: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances.

    Beigel, John H / Hayden, Frederick G

    Cold Spring Harbor perspectives in medicine

    2021  Volume 11, Issue 4

    Abstract: In the last few years, several new direct-acting influenza antivirals have been licensed, and others have advanced in clinical development. The increasing diversity of antiviral classes should allow an adequate public health response should a resistant ... ...

    Abstract In the last few years, several new direct-acting influenza antivirals have been licensed, and others have advanced in clinical development. The increasing diversity of antiviral classes should allow an adequate public health response should a resistant virus to one agent or class widely circulate. One new antiviral, baloxavir marboxil, has been approved in the United States for treatment of influenza in those at high risk of developing influenza-related complications. Except for intravenous zanamivir in European Union countries, no antivirals have been licensed specifically for the indication of severe influenza or hospitalized influenza. This review addresses recent clinical developments involving selected polymerase inhibitors, neuraminidase inhibitors, antibody-based therapeutics, and host-directed therapies. There are many knowledge gaps for most of these agents because some data are not published and multiple pivotal studies are in progress at present. This review also considers important clinical research issues, including regulatory pathways, study designs, endpoints, and target populations encountered during the clinical development of novel therapeutics.
    MeSH term(s) Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Drug Development/organization & administration ; Drug Resistance, Viral/drug effects ; Humans ; Influenza, Human/drug therapy ; Nucleic Acid Synthesis Inhibitors/pharmacology ; Nucleic Acid Synthesis Inhibitors/therapeutic use
    Chemical Substances Antiviral Agents ; Nucleic Acid Synthesis Inhibitors
    Language English
    Publishing date 2021-04-01
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2157-1422
    ISSN (online) 2157-1422
    DOI 10.1101/cshperspect.a038463
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

    Beigel, John H / Tomashek, Kay M / Dodd, Lori E

    The New England journal of medicine

    2020  Volume 383, Issue 10, Page(s) 994

    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Betacoronavirus ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral
    Chemical Substances remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2022236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Influenza.

    Beigel, John H

    Critical care medicine

    2010  Volume 36, Issue 9, Page(s) 2660–2666

    Abstract: Objective: Influenza is a major concern for intensivists in all communities in the U.S. While there is considerable concern whether or not the country will be ready for a pandemic influenza, even seasonal influenza poses a major challenge to hospitals. ... ...

    Abstract Objective: Influenza is a major concern for intensivists in all communities in the U.S. While there is considerable concern whether or not the country will be ready for a pandemic influenza, even seasonal influenza poses a major challenge to hospitals. The objective of this review is to summarize current knowledge of influenza with emphasis on the issues that intensivist will encounter.
    Setting: Intensive care unit in a 450-bed, tertiary care, teaching hospital.
    Methods: Source data were obtained from a PubMed search of the medical literature. PubMed "related articles" search strategies were likewise employed frequently.
    Summary and conclusions: Seasonal influenza causes more than 200,000 hospitalizations and 41,000 deaths in the U.S. every year, and is the seventh leading cause of death in the U.S. Despite this impact there is a shortcoming in knowledge of influenza among many health care workers, and a paucity of clinical data and studies to guide therapy. Intensivists need to recognize the importance of seasonal influenza as a cause of severe morbidity and mortality. This review summarizes current knowledge of the diagnosis, complications, therapy, and infection control measures associated with influenza.
    MeSH term(s) Animals ; Antiviral Agents/therapeutic use ; Birds ; Disease Outbreaks ; Humans ; Infection Control/methods ; Influenza A virus/genetics ; Influenza A virus/isolation & purification ; Influenza in Birds/transmission ; Influenza in Birds/virology ; Influenza, Human/complications ; Influenza, Human/diagnosis ; Influenza, Human/drug therapy ; Influenza, Human/epidemiology ; Reassortant Viruses ; Seasons ; United States/epidemiology
    Chemical Substances Antiviral Agents
    Keywords covid19
    Language English
    Publishing date 2010-03-19
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Intramural ; Review
    ZDB-ID 197890-1
    ISSN 1530-0293 ; 0090-3493
    ISSN (online) 1530-0293
    ISSN 0090-3493
    DOI 10.1097/CCM.0b013e318180b039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1261: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Toward better clinical data in emerging infectious diseases.

    Beigel, John H

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2009  Volume 48, Issue 12, Page(s) 1647–1648

    MeSH term(s) Communicable Diseases, Emerging/drug therapy ; Communicable Diseases, Emerging/pathology ; Communicable Diseases, Emerging/physiopathology ; Communicable Diseases, Emerging/virology ; Humans ; Influenza A Virus, H5N1 Subtype/isolation & purification ; Influenza, Human/pathology ; Influenza, Human/physiopathology ; Influenza, Human/virology ; SARS Virus/isolation & purification ; Severe Acute Respiratory Syndrome/pathology ; Severe Acute Respiratory Syndrome/physiopathology ; Severe Acute Respiratory Syndrome/virology
    Keywords covid19
    Language English
    Publishing date 2009-06-15
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1086/599032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 480: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top